- Home
- MIRM vs NEA Comparison
MIRM vs NEA Comparison
Compare MIRM & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIRM | NEA |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIRM | NEA |
|---|---|---|
| Price | $79.34 | $11.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $92.45 | N/A |
| AVG Volume (30 Days) | ★ 809.5K | 803.4K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $471,794,000.00 | N/A |
| Revenue This Year | $53.78 | N/A |
| Revenue Next Year | $19.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | N/A |
| 52 Week Low | $36.88 | $9.20 |
| 52 Week High | $82.58 | $11.37 |
Technical Indicators
Market Signals| Indicator | MIRM | NEA |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 56.66 |
| Support Level | $77.99 | $11.50 |
| Resistance Level | $82.58 | $11.65 |
| Average True Range (ATR) | 3.21 | 0.09 |
| MACD | 1.03 | 0.01 |
| Stochastic Oscillator | 83.25 | 66.16 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.